Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.authorid0000-0002-0443-6966
dc.contributor.authorİlhan, Yusuf
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorTeker, Fatih
dc.contributor.authorÖnder, Arif Hakan
dc.contributor.authorKöse, Fatih
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorİnanç, Mevlüde
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorKargı, Ayşegül
dc.contributor.authorArak, Hacı
dc.contributor.authorÖzturk, Banu
dc.contributor.authorBeşen, Ali Ayberk
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorOruç, Zeynep
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorBilici, Ahmet
dc.contributor.authorBayram, Selami
dc.contributor.authorDae, Shute Ailia
dc.contributor.authorÖzdoğan, Mustafa
dc.contributor.authorCoşkun, Hasan Şenol
dc.contributor.authorSezgin Göksu, Sema
dc.date.accessioned2022-04-29T08:21:20Z
dc.date.available2022-04-29T08:21:20Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractOBJECTIVE: Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer. METHODS: Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared. RESULTS: A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5-86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95%?CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95%?CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95%?CI 13.0 to 25.1) months in group 1 and 18.3 (95%?CI 15.3 to 21.3) months in group 2 (HR 1.28; 95%?CI 0.91 to 1.80; p=0.15). CONCLUSIONS: There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.
dc.identifier.citationİlhan, Y., Tatlı, A. M., Teker, F., Önder, A. H., Köse, F. ve Geredeli, Ç. (2022). Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecological Cancer, 32(4), 502-507. https://doi.org/10.1136/ijgc-2021-003165
dc.identifier.doi10.1136/ijgc-2021-003165
dc.identifier.endpage507
dc.identifier.issn1048-891X
dc.identifier.issn1525-1438
dc.identifier.issue4
dc.identifier.pmid35086927
dc.identifier.scopus2-s2.0-85128244977
dc.identifier.scopusqualityQ1
dc.identifier.startpage502
dc.identifier.urihttps://doi.org/10.1136/ijgc-2021-003165
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9393
dc.identifier.volume32
dc.identifier.wos000748642300001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.relation.ispartofInternational Journal of Gynecological Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCervical Cancer
dc.subjectCisplatin
dc.subjectVersus Carboplatin Plus
dc.titleCisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu